Drug Overview
Tarceva (erlotinib; Roche/Chugai/Astellas) is an orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. EGFR is part of the ErbB pathway, which is hyperactivated or dysregulated in many cancers, thereby leading to uncontrolled cell growth. In particular, EGFR-activating mutations such as exon 19 deletion (del19) or exon 21 point mutation L858R have previously been identified as contributing to the promotion of tumor cell growth and blocking apoptosis in non-small cell lung cancer. Tarceva reversibly inhibits the kinase activity of EGFR, and has higher binding affinity for EGFR del19 or exon 21 point mutation L858R mutations compared with wild-type receptors. This prevents the initiation of signaling cascades and results in the inhibition of EGFR-dependent proliferation.
Tarceva (erlotinib; Roche/Chugai/Astellas) is an orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. EGFR is part of the ErbB pathway, which is hyperactivated or dysregulated in many cancers, thereby leading to uncontrolled cell growth. In particular, EGFR-activating mutations such as exon 19 deletion (del19) or exon 21 point mutation L858R have previously been identified as contributing to the promotion of tumor cell growth and blocking apoptosis in non-small cell lung cancer. Tarceva reversibly inhibits the kinase activity of EGFR, and has higher binding affinity for EGFR del19 or exon 21 point mutation L858R mutations compared with wild-type receptors. This prevents the initiation of signaling cascades and results in the inhibition of EGFR-dependent proliferation.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Tarceva : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
Figure 1: Tarceva for non-small cell lung cancer – SWOT analysis
Figure 2: The authors drug assessment summary for Tarceva in non-small cell lung cancer
Figure 3: The authors drug assessment summary for Tarceva in non-small cell lung cancer
Figure 4: Tarceva sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
Table 1: Tarceva drug profile
Table 2: Tarceva pivotal trial data in non-small cell lung cancer
Table 3: Tarceva ongoing late-phase clinical trials in non-small cell lung cancer
Table 4: Tarceva late-phase trial data in non-small cell lung cancer
Table 5: Tarceva sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 6: Tarceva patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
